Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin

Naltrexone is an opioid receptor antagonist approved for the treatment of alcohol and opioid use disorders at doses of 50–150 mg/d. Naltrexone has also been prescribed at much lower doses (3–6 mg/d) for the off-label treatment of inflammation and pain. Currently, a compelling mechanistic explanation...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:eNeuro
Hlavní autoři: Metz, Marissa J., Daimon, Caitlin M., Hentges, Shane T.
Médium: Artigo
Jazyk:Inglês
Vydáno: Society for Neuroscience 2021
Témata:
Research Article: Negative Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211470/
https://ncbi.nlm.nih.gov/pubmed/34031099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1523/ENEURO.0087-21.2021
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky